January 26, 2022

Clearmind’s Management Team Explained the Process Required by the FDA to Approve Clearmind’s Patented MEAI Molecule as a Medicine for Treating Alcohol Use Disorder and Binge Drinking

SPEAKERS

Adi Zuloff-Shani, PhD

CEO, Clearmind

Dr. Adi Zuloff-Shani is a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, and a deep understanding of therapeutics development in heavily regulated environments.

Adjunct Prof. Mark Haden

VP Business Development, Clearmind

Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia's School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.

Amit Schwartz, MSc

Clearmind's Director of R&D

Amit has a M.Sc. Degree in Biology from the Faculty of Life Sciences in Bar-Ilan University, Israel. He has also been published on multiple occasions. His research was done in the Neuropsychopharmacology lab, under the supervision of Professor Gal Yadid, who’s on Clearmind’s Scientific Advisory Board.

HOST

Shannon Smadella

Host

Shannon Smadella is an award-winning social entrepreneur and business strategist with deep experience in psychedelic advocacy and organizational leadership. A former board member of MAPS Canada, spokesperson and operations director of World Psychedelics Day, and co-director of the International Psychedelics Awareness Foundation, she has hosted hundreds of interviews with leaders in psychedelic research and policy. She is currently completing her MBA, and oversees community development for Clearmind Medicine.